close
close

Microsoft, Pfizer, Foxconn, Catl and Vodafone

The Tech -Riese Microsoft (MSFT) outlined its vision for the future of AI agents for artificial intelligence (AI) at their annual Build Conference in Seattle on Monday.

Microsoft (MSFT) said that they were agents that operate in individual, organizational, team and end-to-end business contexts. The company said it expected to see what it calls “open agents -Web”, in which AI agents can make decisions and perform tasks for individual users or entire organizations.

AI agents have developed into one of the largest trends in technology, since Microsoft and Customer Relationship Management software Salesforce (CRM) have developed offers in the room. They are semi-or completely autonomous AI software that can carry out certain tasks for users.

Read more: FTSE 100 LIVE: Markets carefully higher than the rigid EU deal brings to parliament

“What we see is the acceleration of AI development and people who switch from Proof of Concepts to work solutions that really drive the business effects,” said Scott Guthrie, Executive Vice President Cloud and AI, to Yahoo Finance.

“We expect the momentum to continue and to be accelerated, since what we call the Agentic Web is created. And our main goal at Microsoft is how we make it easier to keep up with all new technologies,” added Guthrie.

Microsoft (MSFT) also announced on Monday that the KI model Grok 3 by Elon Musk's company Xai was available on its Azure Ai Foundry Marketplace.

The shares of Microsoft (MSFT) closed the session of Monday 1% in the green, but were flat on Tuesday morning in stores in front of the market.

Nasdaqgs – delayed quote USD

At the end: May 19th at 4:00 p.m. GMT-4

The US pharmaceutical manufacturer Pfizer (PFE) announced on Monday evening that it had completed an exclusive license agreement with the Chinese Biopharmaceutical Company 3SBIO (1530.HK) INC for experimental cancer treatment.

Pfizer (PFE) said in an explanation that after the agreement it has an exclusive global license to develop, manufacture and commercialize SSGJ-707 without China.

Read more: Oil slips in the middle of US Iran talks

Treatment is currently enforced in China several clinical studies due to non-small cell cancer, metastatic colon cancer and gynecological tumors.

The US pharmaceutical company said that it would pay 3SBIO 1.25 billion USD (934 million GBP) in advance, followed by up to another milestone for development, regulatory and commercial milestones that are up to one.

The shares in 3SBIO rose by more than 32%on Tuesday, although Pfizer (PFE) shares were hardly changed in the market in front of the market.

Leave a Comment